Hairy Cell Leukemia: Where Are We in 2023?

•• Troussard X, Maître E, Cornet E. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2022;97:226–36. This article is a comprehensive review that touches on future directions such as risk stratification and experimental treatments.

Article  CAS  PubMed  Google Scholar 

Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Epperla N, Zhao Q, Anghelina M, et al. Impact of sex on outcomes in patients with hairy cell leukemia (HCL): an HCL Patient Data Registry (PDR) analysis. J Clin Oncol. 2022. https://doi.org/10.1200/JCO.2022.40.16_suppl.7577.

Article  Google Scholar 

De Propris MS, Musiu P, Intoppa S, et al. Hairy cell leukaemia with low CD103 expression: a rare but important diagnostic pitfall. Br J Haematol. 2022;198:e28–31.

Article  PubMed  Google Scholar 

Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48.

Article  PubMed  PubMed Central  Google Scholar 

Kumar P, Gao Q, Chan A, Lewis N, Sigler A, Pichardo J, Xiao W, Roshal M, Dogan A. Hairy cell leukemia expresses programmed death-1. Blood Cancer J. 2020;10:1–4.

Article  Google Scholar 

Robak P, Jesionek-Kupnicka D, Kupnicki P, Polliack A, Robak T. Bone lesions in hairy cell leukemia: diagnosis and treatment. Eur J Haematol. 2020;105:682–91.

Article  PubMed  Google Scholar 

Doma A, Škerget M, Žagar I. 18F-FDG PET/CT for staging and evaluation of therapy in a patient with unusual hairy cell leukemia presentation. Clin Nucl Med. 2019;44:e458–60.

Article  PubMed  Google Scholar 

Itchaki G, Gurevich K, Gorenberg M, Tadmor T. PB1885: the role of pet CT in hairy cell leukemia. HemaSphere. 2022;6:1764–5.

Article  PubMed Central  Google Scholar 

Notarfranchi L, Russo F, Re F, Mancini C, Martella E, Falini B, Aversa F, Tiacci E. Hairy cell leukaemia mimicking multiple myeloma. Lancet Oncol. 2019;20:e187.

Article  PubMed  Google Scholar 

Rosen DS, Smith S, Gurbuxani S, Yamini B. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine. 2008;9:374–6.

Article  PubMed  Google Scholar 

Hammond WA, Swaika A, Menke D, Tun HW. Hairy cell lymphoma: a potentially under-recognized entity. Rare Tumors. 2017;9:6518.

Article  PubMed  PubMed Central  Google Scholar 

Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14 Suppl 1:57–61.

Jain D, Dorwal P, Gajendra S, Pande A, Mehra S, Sachdev R. CD5 positive hairy cell leukemia: a rare case report with brief review of literature. Cytometry B Clin Cytom. 2016;90:467–72.

Article  PubMed  Google Scholar 

Wang L, Tadros AS, Hoh CK, Wang H-Y. CD10-positive hairy cell leukemia involving multiple deep lymph nodes. Clin Lymphoma Myeloma Leuk. 2016;16:e51–3.

Article  PubMed  Google Scholar 

Kohla S, Ibrahim FA, Aldapt MB, ELSabah H, Mohamed S, Youssef R. A rare case of hairy cell leukemia with unusual loss of CD123 associated with COVID-19 at the time of presentation. Case Rep Oncol. 2020;13:1430–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poret N, Fu Q, Guihard S, Cheok M, Miller K, Zeng G, Quesnel B, Troussard X, Galiègue-Zouitina S, Shelley CS. CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy. Cancer Res. 2015;75:3902–11.

Article  CAS  PubMed  Google Scholar 

Anghelina M, Epperla N, Rogers KA, et al. Down-regulation of CD25 antigen in hairy cell leukemia patients after treatment. Blood. 2018;132:4143.

Article  Google Scholar 

Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tschernitz S, Flossbach L, Bonengel M, Roth S, Rosenwald A, Geissinger E. Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias. Br J Haematol. 2014;165:529–33.

Article  CAS  PubMed  Google Scholar 

• Maitre E, Tomowiak C, Lebecque B, et al. Deciphering genetic alterations of hairy cell leukemia and hairy cell leukemia-like disorders in 98 patients. Cancers. 2022;14:1904. This article describes how mutations in MAP2K1 were the only genetic alteration associated with a poor prognosis.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maitre E, Bertrand P, Maingonnat C, et al. New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. Oncotarget. 2018;9:28866–76.

Article  PubMed  PubMed Central  Google Scholar 

Paillassa J, Maitre E, Troussard X. Hairy cell leukemia (HCL) and HCL variant: updates and spotlights on therapeutic advances. Curr Oncol Rep. 2022;24:1133–43.

Article  CAS  PubMed  Google Scholar 

Maral S, Albayrak M, Dagdas S, et al. Prognostic value of baseline serum lactate dehydrogenase level in patients with hairy cell leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:e616–21.

Article  PubMed  Google Scholar 

Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol. 2011;29:55–66.

Article  CAS  PubMed  Google Scholar 

Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol Off J Am Soc Clin Oncol. 1995;13:974–82.

Article  CAS  Google Scholar 

•• Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:1527–38. Follow-up of a trial demonstrating the deeper and longer responses with the addition of rituximab which effectively is changing how first-line treatment is delivered.

Article  CAS  Google Scholar 

Ravandi F. MRD in HCL: does it matter? Blood. 2018;131:2277–8.

Article  CAS  PubMed  Google Scholar 

Bohn J-P, Dietrich S. Treatment of classic hairy cell leukemia: targeting minimal residual disease beyond cladribine. Cancers. 2022;14:956.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Ravandi F, Kreitman RJ, Tiacci E, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12:165. This is the first consensus on the growing topic of MRD significance in HCL and its value on clinical practice.

Article  PubMed  PubMed Central  Google Scholar 

Chihara D, Kantarjian H, O’Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174:760–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zinzani PL, Lauria F, Salvucci M, Rondelli D, Raspadori D, Bendandi M, Magagnoli M, Tura S. Hairy-cell leukemia and alpha-interferon treatment: long-term responders. Haematologica. 1997;82:152–5.

CAS  PubMed  Google Scholar 

Moore JE, Delibert K, Baran AM, Evans AG, Liesveld JL, Zent CS. Targeted therapy for treatment of patients with classical hairy cell leukemia. Leuk Res. 2021;102:106522.

Article  CAS  PubMed  Google Scholar 

Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk. 2013;13:86–9.

Article  CAS  PubMed  Google Scholar 

Perrotta K, Kiernan E, Bandoli G, Manaster R, Chambers C. Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series. Rheumatol Adv Pract. 2021;5:rkaa074.

Article  PubMed  PubMed Central  Google Scholar 

Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373:1733–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med. 2021;384:1810–23. This study highlighted the value of adding rituximab to a BRAF inhibitor in achieving a higher number of CR and undetectable MRD with a chemotherapy-free combination.

Article  CAS  PubMed  Google Scholar 

Falini B, De Carolis L, Tiacci E. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. Blood. 2022;139:2294–305.

Article  CAS  PubMed  Google Scholar 

Caeser R, Collord G, Yao W-Q, Chen Z, Vassiliou GS, Beer PA, Du M-Q, Scott MA, Follows GA, Hodson DJ. Targeting MEK in vemurafenib-resistant hairy cell leukemia. Leukemia. 2019;33:541–5.

Article 

留言 (0)

沒有登入
gif